Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman M M, Dickson R B
Vincent T. Lombardi Cancer Research Center, Georgetown University Medical School, Washington, D.C. 20007.
J Natl Cancer Inst. 1992 Oct 7;84(19):1506-12. doi: 10.1093/jnci/84.19.1506.
Data obtained from studies of primary human breast cancers and established cell lines indicate that overexpression of the MDR1 gene (also known as PGY1) is associated with decreased expression of steroid hormone receptors and increased expression of epidermal growth factor (EGF) receptors. Other study results indicate that both progestins and triphenylethylene antiestrogens may be substrates for P-glycoprotein, the product of the MDR1 gene. These findings together suggest an association between overexpression of the MDR1 gene and cross-resistance to progestin and antiestrogen therapies.
This study was designed to determine (a) the ability of MDR1 expression to alter tumor sensitivity to hormone therapy and (b) the role of MDR1 expression in expression of functional hormone receptors in human breast cancer.
We transduced MCF-7 cells with MDR1 complementary DNA, using a retroviral vector directing the constitutive expression of the MDR1 gene. Transduced cells (MCF-7MDR1) were examined for ability to produce P-glycoprotein, expression of steroid hormone receptors, and responsivity to antiestrogens. For comparison, we used MCF-7ADR human breast cancer cells, which overexpress MDR1 and have also lost the requirement for 17 beta-estradiol supplementation to form tumors in nude mice. We also investigated the level of EGF-R mRNA expression by using a sensitive RNase protection analysis.
MCF-7MDR1 cells retained both estrogen receptor and progesterone receptor expression as well as sensitivity to 4-hydroxytamoxifen. Expression of the estrogen-inducible pS2 and EGF receptor genes was similar in parental MCF-7 and transduced MCF-7MDR1 cells. EGF receptor expression was increased, and pS2 expression was lost (undetectable) in MCF-7ADR cells.
The data indicate that overexpression of the MDR1 gene alone confers a multidrug-resistant phenotype, but it does not directly result in either cross-resistance to antiestrogens or a loss of steroid hormone receptor expression.
MCF-7MDR1 cells provide an important model for study of the interactions of cytotoxic drugs, hormones, and the MDR1 glycoprotein in human hormone-responsive breast cancer cells.
从原发性人类乳腺癌和已建立的细胞系研究中获得的数据表明,多药耐药基因1(MDR1,也称为PGY1)的过表达与甾体激素受体表达降低以及表皮生长因子(EGF)受体表达增加相关。其他研究结果表明,孕激素和三苯乙烯类抗雌激素药物可能都是MDR1基因产物P-糖蛋白的底物。这些发现共同提示MDR1基因过表达与对孕激素和抗雌激素治疗的交叉耐药之间存在关联。
本研究旨在确定(a)MDR1表达改变肿瘤对激素治疗敏感性的能力,以及(b)MDR1表达在人类乳腺癌功能性激素受体表达中的作用。
我们使用一种逆转录病毒载体转导MCF-7细胞,该载体可指导MDR1基因的组成性表达。对转导后的细胞(MCF-7MDR1)检测其产生P-糖蛋白的能力、甾体激素受体的表达以及对抗雌激素的反应性。作为对照,我们使用了MCF-7ADR人乳腺癌细胞,该细胞过表达MDR1,并且在裸鼠中形成肿瘤时不再需要补充17β-雌二醇。我们还通过使用灵敏的核糖核酸酶保护分析法研究了EGF-R mRNA的表达水平。
MCF-7MDR1细胞保留了雌激素受体和孕激素受体的表达以及对4-羟基他莫昔芬的敏感性。雌激素诱导的pS2和EGF受体基因在亲本MCF-7细胞和转导后的MCF-7MDR1细胞中的表达相似。在MCF-7ADR细胞中,EGF受体表达增加,而pS2表达缺失(无法检测到)。
数据表明,单独的MDR1基因过表达赋予多药耐药表型,但它不会直接导致对抗雌激素的交叉耐药或甾体激素受体表达缺失。
MCF-7MDR1细胞为研究细胞毒性药物、激素和MDR1糖蛋白在人类激素反应性乳腺癌细胞中的相互作用提供了重要模型。